Role of Platelet C-Type Lectin-Like Receptor 2 in Promoting Lung Metastasis in Osteosarcoma.
C-TYPE LECTIN-LIKE RECEPTOR-2
LUNG METASTASIS
OSTEOSARCOMA
PLATELET
PODOPLANIN
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
30
10
2019
revised:
24
04
2020
accepted:
02
05
2020
pubmed:
2
6
2020
medline:
7
7
2021
entrez:
2
6
2020
Statut:
ppublish
Résumé
The overall prognosis of patients with sarcoma-based cancers has changed little in the last 20 years. There is an urgent need to investigate the metastatic potential of these tumors and to develop anti-metastatic drugs. It is becoming increasingly clear that platelets play an important role in the establishment of metastasis of carcinoma cells and could be a useful therapeutic target for patients with carcinoma. However, little is known about the role of platelets in sarcoma progression. Here, we investigated how osteosarcoma progression relates to platelet function to explore the possibility of anti-platelet therapy. We found that, similar to carcinoma cells, podoplanin (also known as Aggrus)-positive osteosarcoma cells induce platelet aggregation and activation. Administration of anti-glycoprotein Ibα (GPIbα, also known as CD42b) antibody reduced the lung metastasis of osteosarcoma. The supernatant from platelets cocultured with osteosarcoma cells contained several growth factors and promoted proliferation, invasiveness, and sphere formation of osteosarcoma cells in vitro. In addition, the development of lung metastasis was highly dependent on direct interaction between osteosarcoma cells and platelets. To explore the therapeutic target, we focused on the interactions between podoplanin on osteosarcoma and C-type lectin-like receptor (CLEC)-2 on platelets. The administration of a depleting antibody against CLEC-2 efficiently suppressed osteosarcoma metastasis into the lung. We also analyzed clinical data from patient samples at primary and metastatic sites. Although GPIbα expression was similar between the two sites, there was a significant increase in podoplanin at the metastatic site compared to that in the primary site, and the level of podoplanin expression in the primary site correlated with patient prognosis. These findings suggest that blockade of interactions between platelets CLEC-2 and osteosarcoma podoplanin represent the most promising therapeutic strategy for preventing the lung metastasis of osteosarcoma. © 2020 American Society for Bone and Mineral Research.
Substances chimiques
Lectins, C-Type
0
Membrane Glycoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1738-1750Informations de copyright
© 2020 American Society for Bone and Mineral Research.
Références
Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154-61.
Wang B, Tu J, Yin J, et al. Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma. Oncotarget. 2015;6:38348-59.
Briccoli A, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005. Surg Oncol. 2010;19:193-9.
Nieto MA. Context-specific roles of EMT programmes in cancer cell dissemination. Nat Cell Biol. 2017;19:416-8.
Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14:611-29.
Saitoh M. Involvement of partial EMT in cancer progression. J Biochem. 2018;164:257-64.
Strilic B, Offermanns S. Intravascular survival and extravasation of tumor cells. Cancer Cell. 2017;32:282-93.
Lou XL, Sun J, Gong SQ, et al. Interaction between circulating cancer cells and platelets: clinical implication. Chin J Cancer Res. 2015;27:450-60.
Haemmerle M, Stone RL, Menter DG, et al. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell. 2018;33:965-83. Review.
Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11:125.
Suzuki-Inoue K, Fuller GL, Garcia A, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2006;107:542-9.
Suzuki-Inoue K, Kato Y, Inoue O, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007;282:25993-6001.
Suzuki-Inoue K, Tsukiji N, Shirai T, et al. Platelet CLEC-2: roles beyond hemostasis. Semin Thromb Hemost. 2018;44:126-34.
Suzuki-Inoue K. Roles of the CLEC-2-podoplanin interaction in tumor progression. Platelets 2018;1-7. Forthcoming. https://doi.org/10.1080/09537104.2018.1478401.
Sasaki T, Shirai T, Tsukiji N, et al. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis. J Thromb Haemost. 2018;16:960-72.
Shirai T, Inoue O, Tamura S, et al. C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice. J Thromb Haemost. 2017;15:513-25.
Saito M, Ichikawa J, Ando T, et al. Platelet-derived TGF-β induces tissue factor expression via the Smad3 pathway in osteosarcoma cells. J Bone Miner Res. 2018;33:2048-58.
Horiguchi K, Sakamoto K, Koinuma D, et al. TGF-β drives epithelial-mesenchymal transition through δEF1-mediated downregulation of ESRP. Oncogene. 2012;31:3190-201.
Shirakihara T, Horiguchi T, Miyazawa M, et al. TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J. 2011;30:783-95.
Ichikawa J, Cole HA, Magnussen RA, et al. Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma. Cancer. 2012;118:2494-506.
Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-68.
Coupland LA, Chong BH, Parish CR. Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res. 2012;72:4662-71.
Takagi S, Takemoto A, Takami M, et al. Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis. Cancer Sci. 2014;105:983-8.
Battinelli EM, Markens BA, Italiano JE Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood. 2011;118:1359-69.
Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A. 2014;111:E3053-61.
Gupta GP, Massague J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest. 2004;114:1691-3.
Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576-90.
Li H, Wang Y, Liu Z, et al. Lack of association between platelet indices and disease stage in osteosarcoma at diagnosis. PLoS One. 2017;12:e0174668.
Thiele W, Rothley M, Dimmler A, et al. Platelet deficiency in Tpo-/- mice can both promote and suppress the metastasis of experimental breast tumors in an organ-specific manner. Clin Exp Metastasis. 2018;35:679-89.
Jackson W 3rd, Sosnoski DM, Ohanessian SE, et al. Role of megakaryocytes in breast cancer metastasis to bone. Cancer Res. 2017;77:1942-54.
Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580-4.
Sannino G, Marchetto A, Kirchner T, et al. Epithelial-to-mesenchymal and mesenchymal-to-epithelial transition in mesenchymal tumors: a paradox in sarcomas? Cancer Res. 2017;77:4556-61.
Sekiguchi T, Takemoto A, Takagi S, et al. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget. 2016;7:3934-46.
Wang Z, Yang X, Wang J, et al. Risk of serious adverse event and fatal adverse event with molecular target anticancer drugs in cancer patients: a meta-analysis. J Cancer Res Ther. 2019;15:1435-49.
Hughes CE, Navarro-Núñez L, Finney BA, et al. CLEC-2 is not required for platelet aggregation at arteriolar shear. J Thromb Haemost. 2010;8:2328-32.
Tsukiji N, Osada M, Sasaki T, et al. Cobalt hematoporphyrin inhibits CLEC-2-podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice. Blood Adv. 2018;2:2214-25.
Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130:1499-506.
Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366:610-8.